AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Aker BioMarine

Director's Dealing Feb 21, 2025

3527_dirs_2025-02-21_c558b79b-9c75-4cba-a35b-3bc9b4c21ff2.html

Director's Dealing

Open in Viewer

Opens in native device viewer

AKBM: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

AKBM: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

February 21, 2025 – Trond Atle Smedsrud, CEO Emerging Business, Aker BioMarine, purchased 6000 shares in Aker BioMarine ASA at an average price of NOK 66 per share on February 21 through his wholly-owned investment company Hawi Holding AS. The shares were acquired on Oslo Børs. Following the transaction, Smedsrud holds a total of 10 410 shares in Aker BioMarine ASA.

For further information, please contact

Christopher Robin Vinter, VP Strategic Finance & IR

Mobile: +47 911 60 820

Email: [email protected]

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Aker BioMarine:

Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.

Talk to a Data Expert

Have a question? We'll get back to you promptly.